The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy

被引:0
|
作者
Liu, Tao [1 ]
Zhou, Ping [2 ]
Jiang, Xin [3 ]
Wang, Na [1 ]
Shou, Jialing [1 ]
Fang, Yuqiang [1 ,4 ]
机构
[1] Army Med Univ, Chongqing Inst Cardiol, Daping Hosp, Dept Cardiol, Chongqing, Peoples R China
[2] First Peoples Hosp Chongqing Liang Jiang New Area, Dept Cardiol, Chongqing 401121, Peoples R China
[3] Peoples Hosp Chongqing Da Du Kou Area, Dept Cardiol, Chongqing, Peoples R China
[4] Army Med Univ, Dept Cardiol, Chongqing Inst Cardiol, Daping Hosp, 10 Changjiang Branch Rd, Chongqing 400042, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
Angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; beta-blockers; dilated cardiomyopathy; PREDICTORS; THERAPY; PREVALENCE; RECOVERY; INSIGHTS;
D O I
10.4103/jrms.jrms_626_21
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a "reversal" effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unclear etiologies and inducements is unknown. Materials and Methods: We studied the effect of the protocol on FSIDCM patients. The effect was investigated in 26 FSIDCM patients. The criteria of "complete reversal" included left ventricular end-diastolic diameter (LVEDD)<= 50 mm for females or <= 55 mm for males and left ventricular ejection fraction (LVEF) >= 45%; the criteria of "partial reversal" was the decreased rate of LVEDD (Delta LVEDD) >10% or the increase rate of LVEF (Delta LVEF) >10%; the criteria of "no reversal" included LVEDD >50 mm for females or >55 mm for males and Delta LVEDD <10%, and LVEF <45% and Delta LVEF <10%. Results: Within the follow-up period, nine patients showed "complete reversal," eight "partial reversal," and nine "no reversal." Improvements in echocardiogram parameters were the most significant in "complete reversal" patients (P < 0.001), followed by "partial reversal" and "no reversal" patients (P < 0.05). The QRS (Q wave, R wave, S wave) duration and symptoms duration in "complete reversal" patients were the shortest, followed by "partial reversal" and "no reversal" patients. Conclusion: ACEIs or ARBs and BBs have a "complete reversal" effect on the left ventricular size and function of some FSIDCM patients. Patients with a narrow QRS and short symptom duration may have a good response.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and risk of appendicitis
    Mukamal, Kenneth J.
    Ghimire, Sanjay
    Pandey, Rudra
    Fiarman, Gale S.
    Gautam, Shiva
    ANNALS OF EPIDEMIOLOGY, 2012, 22 (10) : 747 - 750
  • [32] ANGIOTENSIN-CONVERTING ENZYME INHIBITORS VERSUS ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH HYPERTENSION
    Sanchez, Andres M. Cordova
    Shmorgon, Gary
    Olonoff, Danielle A.
    Ramm, Matthew
    Gualan, Carlos Merino
    Chaudhuri, Debanik
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2074 - 2074
  • [33] Hyperkalemia Associated with Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
    Raebel, Marsha A.
    CARDIOVASCULAR THERAPEUTICS, 2012, 30 (03) : e156 - e166
  • [34] Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
    Koomen, E. R.
    Herings, R. M. C.
    Guchelaar, H. J.
    Nijsten, T.
    CANCER EPIDEMIOLOGY, 2009, 33 (05) : 391 - 395
  • [35] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk
    Potier, Louis
    Roussel, Ronan
    Elbez, Yedid
    Marre, Michel
    Zeymer, Uwe
    Reid, Christopher M.
    Ohman, Magnus
    Eagle, Kim A.
    Bhatt, Deepak L.
    Steg, Philippe Gabriel
    HEART, 2017, 103 (17) : 1339 - 1346
  • [36] Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy
    Ogata, Hitoko
    Ishikawa, Yuka
    Ishikawa, Yukitoshi
    Minami, Ryoji
    JOURNAL OF CARDIOLOGY, 2009, 53 (01) : 72 - 78
  • [37] Effects of Angiotensin-Converting Enzyme Inhibitors and/or Beta Blockers on the Cardiomyopathy in Duchenne Muscular Dystrophy
    Viollet, Laurence
    Thrush, Philip T.
    Flanigan, Kevin M.
    Mendell, Jerry R.
    Allen, Hugh D.
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (01): : 98 - 102
  • [38] Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure - Reply
    Johnson, D
    Cujec, B
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (07) : 1333 - 1334
  • [39] Efficacy of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis
    Llerena-Velastegui, Jordan
    Santamaria-Lasso, Melisa
    Mejia-Mora, Melany
    Santander-Aldean, Mauricio
    Granda-Munoz, Andrea
    Hurtado-Alzate, Claudia
    de Jesus, Ana Clara Fonseca Souza
    Baldelomar-Ortiz, Jurgen
    CARDIOLOGY RESEARCH, 2024, 15 (04) : 281 - 297
  • [40] Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
    Ferrario, CM
    Jessup, J
    Chappell, MC
    Averill, DB
    Brosnihan, KB
    Tallant, EA
    Diz, DI
    Gallagher, PE
    CIRCULATION, 2005, 111 (20) : 2605 - 2610